A protoplast generation and transformation

May 15, 2019

Soybean production around the globe faces signifcant annual yield losses due to pests and diseases. One of the most signifcant causes of soybean yield loss annually in the U.S. is sudden death syndrome (SDS), caused by soil-borne fungi in the Fusarium solani species complex. Two of these species, F. virguliforme and F. brasiliense, have been discovered in the U.S. The genetic mechanisms that these pathogens employ to induce root rot and SDS are largely unknown.

Spotlight

BARENTZYMES

Barentzymes is addressing the need for enzyme based solutions in industrial biotechnology by focusing on the development of new original enzymes from the rich genetic resources of the High North. Barentzymes’ strategy is to take advantage of Norway’s unique marine resources and of strong scientific expertise in enzyme research to develop new enzymes for industrial biotechnology application, initially with a focus on bio-degradation of biological resources for food and non-food applications.

OTHER WHITEPAPERS
news image

State of the Global Biotech Landscape

whitePaper | November 22, 2022

Over the last five years, the global biotech and pharmaceutical landscape has witnessed continued growth. The analysis period encompasses a unique timeframe including the global COVID-19 pandemic.

Read More
news image

U.S. Biopharma Expansions to Europe: Ensuring Successful Build-Out & Market Access

whitePaper | May 24, 2023

The Greater Zurich Area Ltd (GZA), Apellis, and Korn Ferry co-hosted a virtual roundtable for a select group of biopharma leaders interested in expanding their operations into Europe. The panel brought together European launch specialists, talent experts, and Swiss government officials to cover critical questions and guiding principles necessary for a successful European launch, as well as insider knowledge of how to best navigate the regulatory environment.

Read More
news image

WHO considerations on Regulatory Convergence of Cell and Gene Therapy Products

whitePaper | December 16, 2021

Use of cells, tissues, and gene therapy products for the treatment of diseases or 72 physiological conditions has become of wide interest due to their potential to address serious 73 unmet medical needs.

Read More
news image

Optimizing Freeze-Thaw Processes for Cell and Gene Therapy Commercialization

whitePaper | June 23, 2022

Cell and gene therapies require both efficient and reliable freeze-thaw systems. Building the most effective system depends on selecting the right materials and instruments.

Read More
news image

Are Nitrosamines a Concern for Biologic Manufacturers?

whitePaper | March 30, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk.

Read More
news image

Producing therapeutic peptides using biotechnology

whitePaper | October 20, 2022

We began the project by working to the design of a recombinant bacterial strain selection of a strain capable of producing high concentrations of peptides.

Read More

Spotlight

BARENTZYMES

Barentzymes is addressing the need for enzyme based solutions in industrial biotechnology by focusing on the development of new original enzymes from the rich genetic resources of the High North. Barentzymes’ strategy is to take advantage of Norway’s unique marine resources and of strong scientific expertise in enzyme research to develop new enzymes for industrial biotechnology application, initially with a focus on bio-degradation of biological resources for food and non-food applications.

Events